605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Authors :: Arivarasan Karunamurthy
Joe-Marc Chauvin
Robert Morrison
Yulong Bai
Jie Sun
Hong Wang
Douglas Hartman
Julie Stein
Christopher Deitrick
Riyue Bao
Jagjit Singh
Quanquan Ding
Wentao Gao
Drew Hurd
Ornella Pagliano
Amy Rose
Yana Najjar
Jason Luke
David Mauro
Arthur Krieg
James Wooldridge
Dmitri Bobilev
John Kirkwood
Janis Taube
Hyun Jung Park
Hassane Zarour
Diwakar Davar
Source :: Regular and Young Investigator Award Abstracts.
Publication Year :: 2022
Publisher :: BMJ Publishing Group Ltd, 2022.

Full Text Access

Tools